About Sonic Healthcare (ASX: SHL)
Sonic Healthcare Limited provides medical diagnostic services alongside administrative services and facilities to medical practitioners across Australia, the United States, Germany, and a number of other international markets. The company operates primarily through laboratory medicine and pathology testing, covering disciplines such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, and toxicology, as well as a radiology division offering imaging services including MRI, CT, ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry.
Its primary care segment extends the business into general practice clinics, occupational health services, skin cancer clinics, general practice IT solutions, community-based healthcare services, and clinical trials services, reflecting a broad and integrated approach to healthcare delivery. The combination of diagnostic depth and primary care reach positions Sonic Healthcare as a diversified operator across multiple points of the patient care continuum. Incorporated in 1934, the company is headquartered in Sydney, Australia.
MFAM Research
- [BUY] Sonic Healthcare (ASX: SHL) – Medicare Lab Fee Cuts Land Close to Company EstimatesOctober 22, 2026Buy, A$23.70 target, 24.9 per cent upside per institutional sell-side research. Sonic Healthcare's US lab fee cuts land near company estimates.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARLatest Announcements
- Sonic Healthcare (ASX: SHL) – Sonic Healthcare Files Annual ReportSeptember 24, 2026Sonic Healthcare reported a strong financial year with underlying net profit rising 17% to A$621 million on revenue growth of 13%, including organic growth of 5%. The company achieved its earnings guidance and declared total dividends of A$1.08 per share, continuing its progressive dividend history. These results demonstrate the resilience of the diagnostics business model […]
- Sonic Healthcare (ASX: SHL) – Sonic Healthcare FY2026 Financial ReviewAugust 20, 2026Sonic Healthcare reported FY2026 results showing revenue growth of 13 percent to A$10.9 billion, with net profit rising 17 percent to A$621 million and earnings per share growing 14 percent to 125.6 cents. The company achieved its underlying EBITDA guidance at A$1.9 billion, up 11 percent year-on-year. The outperformance of net profit against revenue growth […]
- Sonic Healthcare (ASX: SHL) – Sonic Healthcare FY2026 Full Year ResultsAugust 20, 2026Sonic Healthcare delivered full-year results to June 2026 that met guidance and demonstrated solid operational execution across its sprawling international platform. Revenue grew 13% to $10.87 billion, underpinned by organic growth of 5%, while underlying EBITDA increased 11% to $1.93 billion and underlying earnings per share climbed 14% to 125.6 cents. The result reflects the […]
- Sonic Healthcare (ASX: SHL) – SHL Files FY2026 Preliminary Final ResultsAugust 20, 2026Sonic Healthcare delivered a strong finish to fiscal 2026, with net profit climbing 18.4% to A$608.3 million against the backdrop of 12.7% revenue growth to A$10.9 billion. The outperformance of profit growth relative to revenue growth points to meaningful operational leverage, as the pathology and imaging services provider demonstrably improved its cost structure and operational […]
Financial Summary
Price History
Related Stocks
| Same Industry — Healthcare | Same Sub-Industry — Diagnostics & Research |
|---|---|